Edition:
United States

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

80.89USD
19 Feb 2019
Change (% chg)

-- (--)
Prev Close
$80.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
360,123
52-wk High
$126.15
52-wk Low
$64.73

Latest Key Developments (Source: Significant Developments)

Neurocrine Biosciences And Voyager Therapeutics Form Strategic Development And Commercialization Collaboration
Tuesday, 29 Jan 2019 07:00am EST 

Jan 29 (Reuters) - Voyager Therapeutics Inc ::NEUROCRINE BIOSCIENCES AND VOYAGER THERAPEUTICS FORM STRATEGIC DEVELOPMENT AND COMMERCIALIZATION COLLABORATION FOR PARKINSON’S DISEASE AND FRIEDREICH’S ATAXIA.VOYAGER THERAPEUTICS INC - VOYAGER RECEIVES $165 MILLION UPFRONT, ALONG WITH FUNDING FOR ONGOING DEVELOPMENT OF EACH PROGRAM.VOYAGER THERAPEUTICS INC - VOYAGER RECEIVES UP TO $1.7 BILLION IN POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS.VOYAGER THERAPEUTICS INC - NEUROCRINE BIOSCIENCES HAS AGREED TO FUND CLINICAL DEVELOPMENT OF PHASE 2-3 PIVOTAL PROGRAM FOR VY-AADC.VOYAGER THERAPEUTICS INC - NEUROCRINE BIOSCIENCES HAS AGREED TO FUND DEVELOPMENT THROUGH PHASE 1 CLINICAL TRIAL OF VY-FXN01.  Full Article

Neurocrine Biosciences says Tourette's drug misses main goal in mid-stage trial
Wednesday, 12 Dec 2018 07:30am EST 

Dec 12 (Reuters) - Neurocrine Biosciences Inc ::NEUROCRINE BIOSCIENCES ANNOUNCES TOPLINE DATA FROM PHASE IIB T-FORCE GOLD STUDY DEMONSTRATING VALBENAZINE DID NOT MEET PRIMARY ENDPOINT IN PEDIATRIC PATIENTS WITH TOURETTE SYNDROME.NEUROCRINE BIOSCIENCES INC - NEUROCRINE BIOSCIENCES CONTINUES TO FOCUS ON DEVELOPING TREATMENTS FOR NEUROLOGICAL AND ENDOCRINE RELATED DISORDERS.NEUROCRINE - TYPES OF TREATMENT EMERGENT ADVERSE EVENTS OBSERVED IN PHASE IIB T-FORCE GOLD STUDY CONSISTENT WITH THOSE SEEN IN OTHER VALBENAZINE STUDIES.  Full Article

Neurocrine Biosciences And Jnana Therapeutics Enter Into Strategic Collaboration
Tuesday, 9 Oct 2018 04:01pm EDT 

Oct 9 (Reuters) - Neurocrine Biosciences Inc ::NEUROCRINE BIOSCIENCES AND JNANA THERAPEUTICS ENTER STRATEGIC COLLABORATION TO DISCOVER NOVEL MEDICINES TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS.NEUROCRINE BIOSCIENCES - UNDER TERMS OF AGREEMENT, NEUROCRINE AND JNANA WILL WORK JOINTLY TO IDENTIFY NOVEL COMPOUNDS.  Full Article

AbbVie Announces Positive Results From Phase 3 Study Evaluating Investigational Elagolix
Wednesday, 22 Aug 2018 08:30am EDT 

Aug 22 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 EXTENSION STUDY EVALUATING INVESTIGATIONAL ELAGOLIX IN WOMEN WITH UTERINE FIBROIDS.ABBVIE INC - RESULTS WERE CONSISTENT WITH TWO PIVOTAL PHASE 3 STUDIES (ELARIS UF-I AND ELARIS UF-II) AND NO NEW SAFETY SIGNALS WERE IDENTIFIED.ABBVIE INC - STUDY RESULTS SHOWED ELAGOLIX, IN COMBINATION WITH ADD-BACK THERAPY, REDUCED HEAVY MENSTRUAL BLEEDING FOR UP TO 12 MONTHS.ABBVIE - DATA FROM PHASE 3 PROGRAM WILL SUPPORT REGULATORY SUBMISSION FOR ELAGOLIX IN UTERINE FIBROIDS, ANTICIPATED IN 2019.ABBVIE INC - SECONDARY ENDPOINT RESULTS IN EXTENSION STUDY WERE ALSO CONSISTENT WITH THAT OBSERVED IN PIVOTAL STUDIES.  Full Article

Neurocrine Biosciences Q2 Loss Per Share $0.07
Tuesday, 31 Jul 2018 04:01pm EDT 

July 31 (Reuters) - Neurocrine Biosciences Inc ::NEUROCRINE BIOSCIENCES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.07.Q2 EARNINGS PER SHARE VIEW $-0.17 -- THOMSON REUTERS I/B/E/S.QUARTERLY TOTAL REVENUES $96.91 MILLION VERSUS $6.34 MILLION.  Full Article

Neurocrine Biosciences Says $40 Mln Event-Based Payment To Be Made To Co By Abbvie
Tuesday, 24 Jul 2018 02:41pm EDT 

July 24 (Reuters) - Neurocrine Bioscience::NEUROCRINE BIOSCIENCES - WITH FDA APPROVAL OF ORILISSA, $40 MILLION EVENT-BASED PAYMENT WILL BE MADE TO CO BY ABBVIE UNDER COLLABORATION AGREEMENT.NEUROCRINE BIOSCIENCES - $40 MILLION EVENT-BASED PAYMENT BY ABBVIE TO CO TO BE RECOGNIZED AS REVENUE BY CO IN Q3.  Full Article

AbbVie Receives U.S. FDA Approval Of Orilissa
Tuesday, 24 Jul 2018 08:30am EDT 

July 24 (Reuters) - AbbVie Inc ::ABBVIE RECEIVES U.S. FDA APPROVAL OF ORILISSA™ (ELAGOLIX) FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS.ABBVIE INC - ORILISSA IS EXPECTED TO BE AVAILABLE IN U.S. RETAIL PHARMACIES IN EARLY AUGUST 2018.  Full Article

Neurocrine Biosciences Q1 Loss Per Share $0.47
Monday, 30 Apr 2018 04:01pm EDT 

April 30 (Reuters) - Neurocrine Biosciences Inc ::NEUROCRINE BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.47.Q1 EARNINGS PER SHARE VIEW $-0.30 -- THOMSON REUTERS I/B/E/S.ONGOING OPERATING EXPENSES FOR 2018 ARE NOW EXPECTED TO APPROXIMATE $395 TO $420 MILLION.QTRLY TOTAL REVENUES $71.1 MILLION.Q1 REVENUE VIEW $63.0 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Neurocrine Biosciences appoints Matt Abernethy as CFO
Monday, 20 Nov 2017 04:01pm EST 

Nov 20 (Reuters) - Neurocrine Biosciences Inc ::Neurocrine Biosciences appoints Matt Abernethy as chief financial officer.Neurocrine Biosciences Inc - announced that Matt Abernethy is joining executive management team as chief financial officer​.  Full Article

Neurocrine Biosciences reports Q3 loss per share $0.13
Wednesday, 1 Nov 2017 04:01pm EDT 

Nov 1 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences reports third quarter 2017 results.Q3 loss per share $0.13.Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Says net product sales of $45.8 million for three months ended September 30, 2017​.  Full Article